secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001159036-25-000020
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme CTO Michael J. LaBarre retires effective March 17, 2025; no successor named
--------------------------------------------------------------------------------

- Michael J. LaBarre, SVP and Chief Technical Officer, retired effective March 17, 2025.
- LaBarre notified the company of his decision on the same date.
- He was recognized for contributions to the ENHANZE drug delivery technology.
- No replacement has been announced for the CTO role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000020/0001159036-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000020/halo-20250317.htm
  HTML page:      https://secwatch.observer/filing/0001159036-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer